Table 6.
ADCOMS change scorea | Total N | Changes in CDR-SOBb | Mean Difference (95% CI) |
t-test | p-valuec | |
---|---|---|---|---|---|---|
No meaningful decline n Mean (SD) |
Meaningful decline n Mean (SD) |
|||||
APOE ε4 carrier | ||||||
NACC | 607 |
259 – 0.007 (0.113) |
348 0.301 (0.215) |
– 0.308 (– 0.334; – 0.281) | – 22.79 | < 0.0001 |
ADNI | 105 |
44 0.033 (0.097) |
61 0.309 (0.239) |
– 0.275 (– 0.342; – 0.208) | – 8.11 | < 0.0001 |
APOE ε4 non-carrier | ||||||
NACC | 506 |
224 – 0.019 (0.123) |
282 0.325 (0.234) |
– 0.344 (– 0.376; – 0.312) | – 21.25 | < 0.0001 |
ADNI | 54 |
21 0.041 (0.115) |
33 0.284 (0.193) |
– 0.243 (– 0.327; – 0.158) | – 5.78 | < 0.0001 |
ADCOMS Alzheimer’s Disease Composite Score, ADNI Alzheimer’s Disease Neuroimaging Initiative, CDR-SOB Clinical Dementia Rating Scale Sum of Boxes, CI confidence interval, NACC National Alzheimer’s Coordinating Center, SD standard deviation
aChange score = month 12 score – baseline score
bMeaningful decline: CDR-SOB change ≥ 1.0 from baseline to month 12
ct-test